Long-Acting Injectable Cabotegravir for PrEP Well Tolerated in HPTN 077

Injectable CAB LA
Jul 25, 2017

HPTN 077 results released at IAS 2017 show long-acting injectable cabotegravir (CAB LA) to be well tolerated by men and women and support the dosing schedule currently being used in a phase 3 HPTN study for HIV prevention. The analysis of study data supported further development of CAB LA for HIV prevention in men and women using 600mg (3 mL) injections every eight weeks with the first two injections given four weeks apart.

The study tested the safety, tolerability, acceptability, and pharmacokinetics of the long-acting injectable integrase inhibitor cabotegravir. The study enrolled 199 men and women at low risk for getting HIV at sites in Brazil, United States, Malawi, and South Africa.